Older adults across the European Union are a step closer to replacing two annual jabs with one. In late February 2026, the European Medicines Agency’s expert committee recommended approval of Moderna’s mCombriax, a single mRNA injection designed to protect against both COVID-19 and seasonal influenza in adults aged 50 and older. The European Commission typically finalizes marketing authorization within about 67 days of a positive committee opinion; by late April 2026 that window has passed, and the formal decision is expected to appear in the Union Register imminently if it has not already been published.
mCombriax is the first combined mRNA vaccine targeting both respiratory viruses to receive a positive opinion for this age group in the EU. If national health systems move quickly on procurement, the shot could be available in pharmacies and clinics before the autumn 2026 respiratory virus season begins, potentially simplifying campaigns that have long asked older patients to schedule two separate appointments.
What the regulator found
The EMA’s Committee for Medicinal Products for Human Use (CHMP) issued its positive opinion during a meeting held from 23 to 26 February 2026. The product, submitted by Moderna Biotech Spain S.L., is indicated for adults aged 50 and older, a population that bears a disproportionate share of severe illness and hospitalization from both influenza and COVID-19 each winter.
The regulatory case rests on a randomized clinical trial enrolling roughly 8,000 participants in that age group. Volunteers received either the combined vaccine candidate, known during development as mRNA-1083, or a comparator regimen pairing Moderna’s existing COVID-19 vaccine Spikevax with one of two established flu shots, Fluzone HD or Fluarix. According to the EMA’s public summary, mCombriax produced antibody levels that were statistically non-inferior to those generated by the two separate vaccines given together. Common side effects, chiefly injection-site pain and fatigue, were short-lived and broadly similar to reactions seen with existing mRNA and influenza vaccines.
Full trial results were published in JAMA Network Open, giving independent researchers access to subgroup analyses, follow-up intervals, and a detailed adverse-event profile that go beyond the regulator’s summary. That transparency matters: it allows outside statisticians and epidemiologists to reanalyze key endpoints and test alternative interpretations of the data.
Why a combined shot matters
The practical appeal is simple. Research on vaccine uptake consistently shows that reducing the number of required clinic visits increases completion rates, particularly among people with mobility limitations, chronic conditions, or complex medical schedules. In countries where flu and COVID boosters are offered at the same appointment, uptake is higher than in those where the shots are given weeks apart.
The EMA framed the dual burden of respiratory disease by citing WHO COVID-19 case data and the ECDC seasonal influenza factsheet, both of which confirm that influenza and SARS-CoV-2 continue to circulate and cause serious illness among older Europeans. Those datasets underscore the public-health rationale for a combined vaccine but do not by themselves prove it will reduce disease more effectively than two separate shots. Policymakers must infer potential advantages from experience with other combination vaccines and from behavioral research on uptake.
For stretched health systems, a single-vial approach also promises logistical savings: fewer cold-chain shipments, fewer appointment slots, and less administrative overhead during the busiest weeks of autumn vaccination drives. Whether those theoretical advantages translate into measurably higher protection at the population level will depend on pricing, reimbursement decisions, and how quickly individual EU member states add mCombriax to their national schedules.
What remains uncertain
Several open questions sit between regulatory clearance and real-world impact.
Supply and pricing. Moderna has not publicly detailed rollout timelines or supply agreements with EU governments. Negotiations between individual member states and the manufacturer could lead to uneven access in the first year. Whether mCombriax will be offered free of charge under national immunization programs, as most seasonal flu shots are for older adults, has not been confirmed across all 27 member states.
Strain updates. Both influenza viruses and SARS-CoV-2 continue to mutate. Existing flu vaccines already go through annual strain selection coordinated by the World Health Organization, but adding a COVID-19 component introduces a second variable. If SARS-CoV-2 variants shift on a different timetable than influenza strains, synchronizing both in a single product each year could prove challenging for manufacturers and regulators alike.
Rare side effects. The trial’s roughly 8,000 participants were sufficient for the non-inferiority standard the CHMP applied, but rare adverse events occurring at rates below one in several thousand doses may not surface until millions of people have been vaccinated. The EMA’s risk-management plan will include post-authorization safety commitments, and national pharmacovigilance systems across Europe will play a central role in detecting any signals that emerge at scale.
Real-world effectiveness. The pivotal trial measured immune responses, specifically antibody levels, rather than clinical outcomes such as hospitalizations or deaths prevented. Bridging that gap will require observational studies once the vaccine is in widespread use, comparing hospitalization rates and breakthrough infections among people who received mCombriax versus those who continued with separate shots.
No U.S. approval yet
The EU recommendation does not extend to other jurisdictions. The U.S. Food and Drug Administration has not yet authorized mCombriax, though Moderna has previously indicated it intends to seek approval in the United States. Adults outside the EU should not expect access based on the European decision alone. Regulatory timelines, strain-composition requirements, and advisory committee reviews differ between the EMA and the FDA, so a separate approval process will be required.
What older adults in the EU should do before autumn 2026
Anyone aged 50 or older in the EU who currently receives both a flu shot and a COVID-19 booster each autumn should watch for announcements from their national health authority. Until marketing authorization appears in the EU’s Union Register and national procurement is confirmed, the existing two-shot regimen remains the standard approach.
Checking official health-ministry websites or consulting a regular healthcare provider ahead of the next respiratory virus season is the most reliable way to learn whether a combined shot is available, what eligibility criteria apply, and how it fits alongside other recommended vaccines such as pneumococcal or shingles shots. For clinicians tracking the evolving evidence, the U.S. National Library of Medicine indexes the published trial data and will catalog future post-marketing studies as they appear.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
